- Home
- QMMM vs ALXO Comparison
QMMM vs ALXO Comparison
Compare QMMM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QMMM
- ALXO
- Stock Information
- Founded
- QMMM 2005
- ALXO 2015
- Country
- QMMM Hong Kong
- ALXO United States
- Employees
- QMMM N/A
- ALXO N/A
- Industry
- QMMM
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- QMMM
- ALXO Health Care
- Exchange
- QMMM NYSE
- ALXO Nasdaq
- Market Cap
- QMMM 25.1M
- ALXO 24.0M
- IPO Year
- QMMM 2024
- ALXO 2020
- Fundamental
- Price
- QMMM $1.18
- ALXO $0.59
- Analyst Decision
- QMMM
- ALXO Strong Buy
- Analyst Count
- QMMM 0
- ALXO 6
- Target Price
- QMMM N/A
- ALXO $3.30
- AVG Volume (30 Days)
- QMMM 2.6M
- ALXO 443.0K
- Earning Date
- QMMM 06-10-2025
- ALXO 05-08-2025
- Dividend Yield
- QMMM N/A
- ALXO N/A
- EPS Growth
- QMMM N/A
- ALXO N/A
- EPS
- QMMM N/A
- ALXO N/A
- Revenue
- QMMM $2,698,229.00
- ALXO N/A
- Revenue This Year
- QMMM N/A
- ALXO N/A
- Revenue Next Year
- QMMM N/A
- ALXO N/A
- P/E Ratio
- QMMM N/A
- ALXO N/A
- Revenue Growth
- QMMM N/A
- ALXO N/A
- 52 Week Low
- QMMM $0.54
- ALXO $0.41
- 52 Week High
- QMMM $13.00
- ALXO $9.40
- Technical
- Relative Strength Index (RSI)
- QMMM N/A
- ALXO 55.42
- Support Level
- QMMM N/A
- ALXO $0.52
- Resistance Level
- QMMM N/A
- ALXO $0.59
- Average True Range (ATR)
- QMMM 0.00
- ALXO 0.04
- MACD
- QMMM 0.00
- ALXO 0.02
- Stochastic Oscillator
- QMMM 0.00
- ALXO 73.04
About QMMM QMMM HOLDINGS LIMITED
QMMM Holdings Ltd is a digital advertising and marketing production services company. It operates through its two wholly owned subsidiaries: ManyMany Creations and Quantum Matrix. It has used interactive design, animation, art-tech and virtual technologies in over 500 commercial campaigns. The company has worked with large domestic and international banks, real estate developers, amusement parks, top international athletic apparel and footwear brands, and luxury cosmetic products and international brands for their advertising and creation work in Hong Kong. Its clients include local and international banks, real-estate developers, luxury brands, high fashion houses, and theme parks.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.